BREAKING: Melanoma Adjuvant Therapy Faces Reimbursement Concerns The lack of definitive overall survival data for adjuvant therapy in stage III melanoma is prompting worries about reimbursement and treatment… The post Melanoma Adjuvant Therapy: OS Data Gaps Explained appeared first on NewsyList. Source link
TOPLINE: Droplet digital polymerase chain reaction (PCR) measurements of circulating tumor DNA (ctDNA) identify patients with stage III melanoma who are at high risk for early recurrence during adjuvant targeted therapy. The blood-based biomarker outperforms traditional prognostic indicators including tumor mutational burden and interferon gamma gene expression. METHODOLOGY: Cell-free ctDNA is an established measure of … Read more
CORONADO, CALIF. — According to Christopher J. Arpey, MD, there is no single best approach to treating lentigo maligna (LM) and LM melanoma (LMM), but Mohs micrographic surgery is a sensible option in cases where margin size is critical and tissue conservation with precision is essential. At the annual Melanoma and Cutaneous Oncology Symposium, Arpey, … Read more
The treatment landscape for melanoma saw significant advancements in 2024, as highlighted by Elisa Funck-Brentano, MD, PhD, from Ambroise-Paré Hospital in Paris, France, during her presentation at the 2024 Dermatology Days of Paris conference in Paris. Checkpoint Inhibitors in Neoadjuvant Therapy The standard approach for treating resectable stage III melanoma with locoregional metastases has traditionally … Read more
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Article PubMed Google Scholar Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. PubMed Google Scholar … Read more